The Diagnostic and Predictive Value of Different Biomarkers in Pancreatic Juice and blood in Patients with Pancreatic Cancer
Recruiting
- Conditions
- Pancreatic cancer
- Registration Number
- NL-OMON25284
- Lead Sponsor
- Erasmus University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
All patients with (suspected) pancreatic cancer that undergo an EUS either as part of a diagnostic process or for fiducial placement prior to treatment.
Exclusion Criteria
A potential subject that is younger than 18 years old will be excluded from participation in this study.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ct-DNA levels in pancreatic juice and serum in relation to (progression-free) survival.
- Secondary Outcome Measures
Name Time Method Ct-DNA levels in pancreatic juice and serum<br /><br>CINdex in pancreatic juice and serum<br /><br>The cellular composition of pancreatic juice (Number of cancer cells, Clonality of the cancer cells, Intracellular (single-cell) mutations, capability to grow organoids)<br /><br>Molecular composition of pancreatic juice (Levels of pro- and anti-inflammatory molecules, inhibitory and activating immune cells, molecules related to fibrosis)<br /><br>(Progression free) survival (assessed after 12 and 18 months)<br /><br>Tumour size<br /><br>Presence of metastases